Table 2.
Summary of AEs by treatment group according to MedDRA system
| MedDRA system organ class (preferred term) | BMAC (N = 107) | SVF (N = 109) | UCT (N = 116) | CSI (N = 108) | All subjects (N = 440) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | |
| Musculoskeletal connective tissue disorders | ||||||||||
| Arthralgia | 27 (25.2) | 17.3, 34.6 | 25 (22.9) | 15.4, 32.0 | 30 (25.9) | 18.2, 34.8 | 28 (25.9) | 18.0, 35.2 | 110 (25.0) | 21.0, 29.3 |
| Joint stiffness | 13 (12.1) | 6.6, 19.9 | 6 (5.5) | 2.0, 11.6 | 8 (6.9) | 3.0, 13.1 | 8 (7.4) | 3.3, 14.1 | 35 (8.0) | 5.6, 10.9 |
| Joint swelling | 19 (17.8) | 11.0, 26.3 | 16 (14.7) | 8.6, 22.7 | 28 (24.1) | 16.7, 33.0 | 8 (7.4) | 3.3, 14.1 | 71 (16.1) | 12.8, 19.9 |
The safety population is defined as the 440 subjects who received study treatment. The AEs are those with an incidence of at least 5%. MedDRA denotes Medical Dictionary for Regulatory Activities, version 21.1.
95% CIs that do not overlap are statistically significant.